JinYao Pharmaceutical hits six consecutive limit-ups,炒 concept "Love You No Negotiation"?

Asking AI · What market psychology is hidden behind the invalid clarification by Tianjin Pharmaceutical?

CNR Beijing, April 3 (Reporter Zou Xuchen) On April 3, Tianjin Pharmaceutical (600488.SH) hit the daily limit again, achieving six consecutive limit-ups with a total increase of 76.9% over the period.

It should be noted that in the announcement released on the evening of April 2, Tianjin Pharmaceutical explicitly stated that after self-examination, the company noticed that the market had classified it as an innovative drug concept. Currently, the company’s research and development mainly focus on generic drugs, with no ongoing innovative drug projects.

Related staff from Tianjin Pharmaceutical also told CNR Finance on April 3 that the company does not belong to the innovative drug concept stock and hopes that all market parties avoid misreading and view the company’s stock price rationally.

On the evening of April 3, Tianjin Pharmaceutical issued another announcement regarding abnormal stock trading fluctuations, reiterating that there is a clear misinterpretation of the market’s hype around the company’s innovative drug concept, emphasizing that the company’s current R&D focus remains on generic drugs and that there are no ongoing innovative drug projects.

Multiple reasons may be behind this

On April 3, Tianjin Pharmaceutical hit the daily limit within less than a minute after opening, with still 265k buy orders at the limit at the close, and the total trading volume for the day surged to 652 million yuan, with a turnover rate of 8.59%. This is the sixth limit-up since March 27.

Following continuous large increases, between March 30 and April 2, Tianjin Pharmaceutical released four announcements about abnormal stock trading or risk warnings.

CNR Finance staff noticed that only the announcement on the evening of April 2 mentioned the innovative drug concept. In response, relevant staff from Tianjin Pharmaceutical explained that the company’s risk investigation is progressing step by step. The additional statement this time aims to provide a more comprehensive risk warning to the market and guide investors to view stock price fluctuations rationally.

When asked further about the specific source of market misreading, the staff declined to comment directly, only emphasizing that all information must be based solely on the company’s publicly disclosed content.

Lu Suiqi, an emeritus associate professor at Peking University’s School of Economics, analyzed that the stock price surge caused by concept misreading may have multiple underlying reasons: First, the market lacks mainstream investment themes, and incremental funds are eager to find outlets; second, there may be intentional or unintentional guidance by behind-the-scenes institutions; third, interpretations by some intermediaries and self-media have played a role in fueling the hype; fourth, the timeliness of the company’s information disclosure is insufficient; fifth, ordinary investors’ ability to discern market information needs improvement.

Preliminary review by the reporter found that before Tianjin Pharmaceutical issued its clarification on April 2, some self-media linked the company to the innovative drug concept.

This image appears AI-generated

Some self-media article. Image source: Reporter’s compilation

Although Tianjin Pharmaceutical clarified the innovation drug concept on April 2 and stated that the company’s main business has not undergone significant changes, the short-term sharp and continuous rise in stock price may be due to overheated market sentiment and irrational speculation, with the risk of rapid decline at any time. However, this clarification did not stop the stock price from rising, and on April 3, the company’s stock still hit the limit-up.

Nankai University Professor of Finance Tian Lihui told CNR Finance that the core reason is market “labeling speculation” and “liquidity game” under information overload. When innovative drugs become a market hotspot, some funds no longer scrutinize the company’s fundamentals and R&D pipeline but buy based on the broad label of “pharmaceutical enterprise” driven by emotion. This “buy first, verify later” behavior, combined with the liquidity locking effect of limit-ups, creates a self-reinforcing upward cycle. The reason why the company’s clarification announcements fail is that short-term speculative funds do not care about the truth, only whether there is later capital to take over. This is a typical market failure phenomenon of “noise masking signals.”

Beware of “ineffective clarification” as a risk signal

Qianhai Open Source Fund Chief Economist Yang Delong believes that recently, the innovative drug sector has performed quite well. Against this background, some companies that are not primarily engaged in innovative drugs have experienced stock price surges due to market misreading as innovative drug concept stocks. This kind of hype driven by concept misreading has long existed.

He pointed out that this phenomenon reflects some investors’ enthusiasm for “hype concepts,” with many investors blindly following trends without in-depth research into the company’s main business and core competitiveness, ultimately leading to irrational over-speculation.

Yang Delong emphasized that the price increases caused by concept hype are often unsustainable, and the related stocks are likely to experience a return to value afterward. Investors should be cautious of follow-the-leader risks, return to the company’s fundamentals, and judge whether the stock truly possesses the relevant concept attributes from the perspective of core competitiveness.

Such concept hype is not an isolated case. Previously, Huadian Liaoning (600396.SH) experienced similar situations. From March 16 to March 25, Huadian Liaoning hit limit-up in all eight trading days. During this period, the company issued five announcements about abnormal stock trading or risk warnings, explicitly stating that after verification, the company’s production and operation activities are normal, with main business in thermal power generation, and coal-fired capacity accounting for 82.56%. Daily operations had no major changes, but these risk warnings did little to curb the continuous rise in stock price, with limited effect.

It was not until the evening of March 26 that Huadian Liaoning issued an announcement on abnormal trading and serious abnormal fluctuations, explicitly stating that the company “does not involve the coal-electricity coordination project,” which finally broke the hype. On March 27, Huadian Liaoning’s stock price experienced significant fluctuations and then declined. By the close on April 3, its stock price had fallen 25.4% from the high point on March 27. The reporter’s preliminary review found that even now, articles linking Huadian Liaoning to the coal-electricity coordination can still be found online.

This image appears self-generated

Some self-media article. Image source: Reporter’s compilation

Tian Lihui believes that this phenomenon exposes the stubborn disease of concept hype in the A-share market, where price discovery is hijacked by short-term sentiment. For investors, two principles should be adhered to: first, rely on official company announcements rather than market rumors or sector labels; second, be alert to “ineffective clarification” signals—when a company repeatedly denies a concept but the stock still hits the limit-up, it often means hype has diverged from fundamentals, and chasing high at this point is akin to gambling. Rational strategies involve not participating in hype beyond one’s understanding and not treating luck as skill.

Liu Zhigeng, a well-known expert in finance and taxation, told CNR Finance that this kind of “unsubstantiated concept hype” is essentially a short-term game under asymmetric capital and information, violating value investing logic. In the short term, stock price surges may profit a few speculators, but in the long run, prices will inevitably revert to the company’s fundamentals, and follow-up investors often suffer losses. Moreover, such behavior disrupts market pricing mechanisms, increases volatility, and may trigger regulatory accountability, damaging the compliance image of listed companies.

Lu Suiqi also offered related advice, suggesting that regulators and exchanges could focus on investigating the trading records of behind-the-scenes institutions and whether major shareholders or senior executives of listed companies have abnormal trading traces, to curb such behavior. He also reminded investors to stay vigilant about market hype risks, establish rational investment concepts, and avoid blindly chasing gains or selling in panic.